Rare Melanomas and Quality of Life: A Report From the Melanoma Research Alliance’s RARE Registry
Journal of the Advanced Practitioner in Oncology · 09.11.2026 · 17 (7)
DOI: 10.6004/jadpro.2026.17.7.31 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Advanced Practitioner in Oncology, online erschienen am 09.11.2026. Verfasst von Jennifer E. Ward und 16 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Acral melanoma (AM) and mucosal melanoma (MM) are rare melanoma subtypes with poorer outcomes compared with the most common cutaneous melanoma (CM) subtype. Limited patient-centered research on quality of life (QOL) has been conducted in these rare melanomas. We characterized patient-reported physical and mental functioning among individuals enrolled in the Melanoma Research Alliance’s RARE Registry.
Methods
We performed a cross-sectional analysis of 230 registry participants (64 AM, 107 MM, 59 non-acral CM) who completed the Short Form-12 (SF-12); Physical (PCS) and Mental (MCS) Component Summary T-scores were categorized (≤ 1 SD, ± 1 SD, ≥ 1 SD) and compared with expected normative proportions. Differences in PCS and MCS T-scores among cohorts were assessed while controlling for demographic and health variables.
Results
In AM and MM, PCS and MCS scores deviated significantly from normative expectations (p < .004), with more falling ≥ 1 SD below the US population mean. In CM, MCS but not PCS scores differed from expected norms (MCS: p < .001; PCS: p = .566). Unadjusted PCS scores were significantly lower in AM and MM compared to CM (p = .005), whereas MCS scores did not differ among cohorts (p = .172). Multiple clinical covariates were significant predictors of PCS and MCS scores.
Conclusions
Participants with AM and MM report clinically meaningful differences in physical and mental QOL compared with population norms; CM participants showed normal physical but poor mental functioning. Routine screening for physical and mental functioning is recommended to identify unique patient needs. Early referral to appropriate supportive care may be warranted, independent of medical and global prognostic factors.
Zitieren
APA
Ward, J. E., PhD, Torre, K. D. L., PhD, Fischer, R. A., PhD, Starink, N., MPH, Asgari, M. M., MD, MPH, Hurlbert, M. S., PhD, Levy, J. B., PhD, Scales, J. L., & PhD (2026). Rare Melanomas and Quality of Life: A Report From the Melanoma Research Alliance’s RARE Registry. Journal of the Advanced Practitioner in Oncology, 17(7). https://doi.org/10.6004/jadpro.2026.17.7.31
Vancouver
Ward JE, PhD, Torre KDL, PhD, Fischer RA, PhD, et al. Rare Melanomas and Quality of Life: A Report From the Melanoma Research Alliance’s RARE Registry. Journal of the Advanced Practitioner in Oncology. 2026;17(7). doi:10.6004/jadpro.2026.17.7.31
BibTeX
@article{Ward2026,
author = {Ward, Jennifer E. and PhD and Torre, Kristine De La and PhD and Fischer, Rachel A. and PhD and Starink, Nicholas and MPH and Asgari, Maryam M. and MD and MPH and Hurlbert, Marc S. and PhD and Levy, Joan B. and PhD and Scales, Jessica L. and PhD},
title = {Rare Melanomas and Quality of Life: A Report From the Melanoma Research Alliance’s RARE Registry},
journal = {Journal of the Advanced Practitioner in Oncology},
year = {2026},
volume = {17},
number = {7},
doi = {10.6004/jadpro.2026.17.7.31}
}
EUVIMED